NEW YORK (GenomeWeb News) – Enzo Biochem has filed a shelf registration to separately offer up to $50 million of its securities and another $18 million of its common stock.

Enzo filed two prospectuses in a Form S-3 with the US Securities and Exchange Commission on Thursday. In one, the New York-based life science reagents and diagnostic testing firm said it may offer from time to time its common stock, preferred stock, depositary shares, debt securities, warrants, and units totaling no more than $50 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.